Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Genetics

Pharmaceutical

Clinical Trials

Financial Results

More Like This

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights